Physician profile
Suzanne Cox
NPI 1710272083
$2,207.15
in general payments reported to CMS, 2019-2025
24 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $614 · 2023: $276 · 2024: $255 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $507.72 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $222.55 | 2021-2025 | Uzedy |
| Supernus Pharmaceuticals, INC. | $152.64 | 2021-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $132.11 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.78 | 2022-2025 | Caplyta |
| Neos Therapeutics, Lp | $109.90 | 2021-2024 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $106.09 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $96.38 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $93.01 | 2021-2025 | Fanapt |
| Corium, LLC | $91.00 | 2022-2025 | Azstarys |
| Tris Pharma INC | $81.87 | 2023-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $73.50 | 2022-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $65.05 | 2025 | Auvelity |
| Lundbeck LLC | $60.20 | 2021 | |
| Sunovion Pharmaceuticals INC. | $53.77 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.55 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $30.82 | 2022 | |
| Ironshore Pharmaceuticals INC. | $30.05 | 2023 | Jornay Pm |
| Sage Therapeutics, LLC | $25.77 | 2021-2022 | |
| Adlon Therapeutics L.P. | $25.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2024 | |
| Brainsway USA INC | $15.24 | 2023 | |
| Vertical Pharmaceuticals, LLC | $13.25 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.